WFG Advisors LP raised its stake in GlaxoSmithKline PLC (NYSE:GSK) by 7.6% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 5,392 shares of the pharmaceutical company’s stock after buying an additional 379 shares during the period. WFG Advisors LP’s holdings in GlaxoSmithKline PLC were worth $227,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Bronfman E.L. Rothschild L.P. boosted its position in GlaxoSmithKline PLC by 45.4% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 2,410 shares of the pharmaceutical company’s stock valued at $102,000 after buying an additional 753 shares during the last quarter. Heritage Trust Co acquired a new position in GlaxoSmithKline PLC during the first quarter valued at about $123,000. Advisory Services Network LLC acquired a new position in GlaxoSmithKline PLC during the first quarter valued at about $137,000. Menora Mivtachim Holdings LTD. acquired a new position in GlaxoSmithKline PLC during the fourth quarter valued at about $138,000. Finally, Advisors Preferred LLC acquired a new position in GlaxoSmithKline PLC during the first quarter valued at about $140,000. Hedge funds and other institutional investors own 8.97% of the company’s stock.

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Shares of GlaxoSmithKline PLC (NYSE:GSK) opened at 43.82 on Friday. The company’s 50 day moving average price is $42.98 and its 200-day moving average price is $40.87. GlaxoSmithKline PLC has a 1-year low of $37.20 and a 1-year high of $45.58. The firm has a market cap of $107.05 billion, a price-to-earnings ratio of 50.14 and a beta of 1.04.

GlaxoSmithKline PLC (NYSE:GSK) last issued its earnings results on Wednesday, April 26th. The pharmaceutical company reported $0.62 EPS for the quarter, meeting analysts’ consensus estimates of $0.62. GlaxoSmithKline PLC had a return on equity of 113.31% and a net margin of 5.48%. The firm had revenue of $9.23 billion for the quarter, compared to the consensus estimate of $9.09 billion. Equities analysts expect that GlaxoSmithKline PLC will post $2.82 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, July 13th. Shareholders of record on Friday, May 12th will be paid a $0.483 dividend. The ex-dividend date is Wednesday, May 10th. This represents a $1.93 dividend on an annualized basis and a yield of 4.41%. This is an increase from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. GlaxoSmithKline PLC’s payout ratio is 232.53%.

WARNING: This news story was posted by Financial Market News and is the property of of Financial Market News. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The original version of this news story can be read at https://www.financial-market-news.com/2017/06/17/glaxosmithkline-plc-gsk-shares-bought-by-wfg-advisors-lp.html.

GSK has been the subject of several research analyst reports. BNP Paribas cut their price objective on GlaxoSmithKline PLC to $37.00 in a research report on Thursday, April 6th. TheStreet upgraded GlaxoSmithKline PLC from a “c” rating to a “b” rating in a research report on Friday, May 19th. Liberum Capital initiated coverage on GlaxoSmithKline PLC in a research report on Thursday, March 9th. They issued a “buy” rating for the company. Jefferies Group LLC reiterated a “buy” rating on shares of GlaxoSmithKline PLC in a research report on Sunday, February 19th. Finally, Berenberg Bank upgraded GlaxoSmithKline PLC from a “hold” rating to a “buy” rating in a research report on Friday, May 26th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and eleven have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $45.25.

About GlaxoSmithKline PLC

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline PLC (NYSE:GSK).

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.